Roger B Cohen MD

PubMed

• Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patie...
  Roger B Cohen, Antonio Jimeno, Jennifer Hreno, Lova Sun, Marie Wallén-Öhman
  Investigational New Drugs. 2025-05-01
• Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
  Adam Barsouk, Omar Elghawy, Alex Watts, Lauren Reed-Guy, William Tompkins
  Lung Cancer. 2025-05-01
• INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
  Jérôme Fayette, Lisa Licitra, Kevin Harrington, Robert Haddad, Lillian L Siu
  Clinical Cancer Research. 2025-04-29

Journal Articles

• Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus–Associated Oropharyngeal Carcinoma in Older Patients  
  Harman S Parhar, Karthik Rajasekaran, Ara A Chalian, Christopher H Rassekh, Roger B Cohen, Joshua Bauml, Gregory S Weinstein, Robert M Brody, JAMA Otolaryngology–Head & Neck Surgery
• Cisplatin Versus Cetuximab with Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: An Analysis of Veterans Health Affairs Data  
  Ravi Vinnakota, Keith Sigel, Joshua M Bauml, Roger B Cohen, Nevena Damjanov, Corey J Langer, Ronac Mamtani, Charu Aggarwal, Christina Knepley, Juan Wisnivesky, Cancer
• Immunotherapy Targeting HPV 16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer  
  Gregory S Weinstein, Charu Aggarwal, Roger B Cohen, Joshua Bauml, Alexander Lin, Clinical Cancer Research

Lectures

• A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses. 
  2019 ASCO Annual Meeting - 6/1/2019
• 10th International Congress on Targeted Therapies in Cancer 
  Physicians' Education Resource, LLC, Washington, Dist Of Col - 8/17/2012